CoChat
Sign Up
Cited by 179Systemic Lupus Erythematosus ResearchBlood Coagulation and Thrombosis MechanismsVenous Thromboembolism Diagnosis and Management

The DOI matches its Crossref record; 67 of the 68 references it cites were found in a registry or an index.

Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: A systematic review and meta-analysis

Reynaud, Quitterie, Lega, Jean-Christophe, Mismetti, Patrick, Chapelle, Céline, Wahl, Denis, Cathébras, Pascal, Laporte, Silvy·2014·Autoimmunity Reviews
DOI 10.1016/j.autrev.2013.11.004
Open this paper in CoChat — free account

Abstract

Aim To evaluate the magnitude of venous and arterial thrombosis risk associated with antiphospholipid antibodies (APLs) in adults without systemic lupus erythematosus (SLE).Methods Case-control and cohort studies were selected from the MEDLINE and Cochrane Library databases. Two investigators independently extracted data on study design, patient characteristics, venous and arterial events and exposure to APLs, including lupus anticoagulant (LA), anticardiolipin (aCL), anti-β2 Glycoprotein I (β2GpI), anti-prothrombin (aPT), anti-phosphatidyl serine (aPS), and anti-phosphatidyl ethanolamine (aPE).Results 30 studies were included (16,441 patients). The odds ratio (OR) for venous thrombosis was 6.14 (95% confidence interval [CI] 2.74-13.8) in LA-positive patients (5 studies, 1650 patients) and 1.46 (CI 1.06-2.03) in aCL-positive patients (12 studies, 5375 patients). None of the associations with more recently identified APLs was significant, but fewer studies were available. For arterial thrombosis, the OR for LA and aCL was 3.58 (CI 1.29-9.92) and 2.65 (CI 1.75-4.00) respectively. The associations between β2GpI, aPT and aPS and the risk of arterial thrombosis were also significant, the OR being 3.12 (CI 1.51-6.44), 2.95 (CI 1.31-6.66) and 6.00 (CI 3.07-11.7), respectively. Owing to the heterogeneity of cut-off values for each APL assay, we were unable to perform any sensitivity analysis to determine the optimal value. The presence of low-quality studies may have led to overestimation of the magnitude of the associations.Conclusions LA and aCL were significantly associated with an increased risk of thrombosis, especially arterial, in patients without SLE. Systematic thromboprophylaxis in high-risk patients with APL should be evaluated.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.autrev.2013.11.004

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 2

  1. Fijnheer, 1994, Antiphospholipid antibodies in patients with thrombo-embolic disease, Lupus, 3, 361
  2. Simioni, 1994, Lupus anticoagulant and antiphospholipid antibodies in outpatients with clinically suspected DVT, Lupus, 3, 361

Cited by

Sorted by citations

See all 179

Related

See all

Metadata

Authors
Reynaud, Q., Lega, J.-C., Mismetti, P., Chapelle, C., Wahl, D., Cathébras, P., & Laporte, S.
Affiliations
  • Centre Hospitalier Universitaire de Saint-Étienne (FR)
  • Lyon 1 Université (FR)
  • Inserm (FR)
Corresponding author
Lega, Jean-Christophe
ORCID
Venue
Autoimmunity Reviews
Publisher
Elsevier BV
Published
2014-06
Volume
13
Issue
6
Pages
595-608
ISSN
1568-9972 (ISSN-L)
DOI
10.1016/j.autrev.2013.11.004
OpenAlex
W2020778344
Cited by
179
References
68
Citations by year
2026: 5 · 2025: 10 · 2024: 16 · 2023: 1 · 2022: 12 · 2021: 13 · 2020: 19 · 2019: 15 · 2018: 21 · 2017: 19 · 2016: 18 · 2015: 22 · 2014: 8
FWCI
3.68
Type
journal article
Language
en
Open access
closed
Locations
  • Autoimmunity Reviews (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Keywords
antiphospholipid antibodies, venous thrombosis, arterial thrombosis, lupus anticoagulant, anticardiolipin antibodies, anti-beta2-glycoprotein I antibodies, anti-prothrombin antibodies, antiphosphatidylserine antibodies, thrombosis risk, thromboprophylaxis
MeSH terms
Adult, Humans, Lupus Erythematosus, Systemic, Risk Factors, Thrombosis, Cohort Studies, Case-Control Studies, Lupus Coagulation Inhibitor, Antiphospholipid Syndrome, Antibodies, Antiphospholipid, beta 2-Glycoprotein I

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review